| Title: | Construction of Precision Clinical-Proteomics Risk model Based on Machine Learning for Predicting Heart Failure in Type II Diabetes Mellitus |
| Journal: | Nutrition Metabolism and Cardiovascular Diseases |
| Published: | 25 May 2026 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/42225438/ |
| DOI: | https://doi.org/10.1016/j.numecd.2026.104806 |
Publication 19916
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
BACKGROUND AND AIMS: Heart failure (HF) is a severe complication in type 2 diabetes mellitus (T2DM), but current risk stratification scores have limited predictive accuracy. We aimed to develop novel prediction tools integrating clinical variables with proteomics to improve risk stratification of hospitalization for HF in T2DM.</p>
METHODS AND RESULTS: In this study, we included 2111 UK Biobank participants with T2DM but no prior HF, and profiled 2920 proteins to predict 10-year incident HF hospitalization. Participants were randomly divided into training (70%), tuning (10%), and validation (20%) sets.Three prediction models were developed: a Clinical model based on demographic characteristics, comorbidities, medication use, and laboratory indices; a Protein model based on 40 proteins selected by the Light Gradient Boosting Machine (LGBM); and the Clinical OMics and Protein ASSessment for Heart Failure (COMPASS-HF) model, which integrated both clinical variables and the LGBM-selected proteins. Models were evaluated for area under the curve (AUC), sensitivity, and specificity. During follow-up, 168 participants (7.96%) developed incident HF. The COMPASS-HF model showed better discrimination than the Clinical model, with an AUC of 0.897 (95% CI: 0.850-0.945) versus 0.790 (95% CI: 0.723-0.856). It also demonstrated higher sensitivity (0.882; 95% CI: 0.725-0.967) and consistent performance in subgroups. COMPASS-HF effectively stratified risk of hospitalization for HF, with cumulative incidence rates of 31.9% in the high-risk group and 1.2% in the low-risk group.</p>
CONCLUSIONS: By combining clinical and proteomic variables, we developed a high-performance HF prediction model for T2DM, enabling precise risk stratification and informing early intervention strategies.</p>
12 Authors
- Runnan Shen
- Chaoyu Xie
- Yechao Huang
- Jiexin Li
- Pinrong Dong
- Kangyuan Huang
- Qian Chen
- Yingsi Ou
- Yang Chen
- Jingfeng Wang
- Kai Huang
- Yangxin Chen
Enabling scientific discoveries that improve human health